SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal - Quaterly Results

09 Nov 2022 Evaluate
The Revenue for the quarter ended  September 2022 of Rs. 5587.50 millions grew by 19.12 % from Rs. 4690.60 millions.Net profit of the cmpany stood at Rs. 248.40 millions for the quarter ended September 2022 a decline of -43.61% from Rs. 440.50 millions  in the same quarter last year.Operating Profit reported a sharp decline to 709.80 millions from 917.60 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 5587.50 4690.60 19.12 9375.40 9258.40 1.26 19427.20 17204.40 12.92
Other Income 12.50 8.70 43.68 45.20 40.50 11.60 48.90 49.80 -1.81
PBIDT 709.80 917.60 -22.65 969.20 1906.60 -49.17 3454.50 3278.70 5.36
Interest 108.00 79.60 35.68 220.90 159.50 38.50 312.10 362.00 -13.78
PBDT 601.80 838.00 -28.19 748.30 1747.10 -57.17 3142.40 2916.70 7.74
Depreciation 274.10 242.00 13.26 539.10 467.60 15.29 956.70 852.40 12.24
PBT 327.70 596.00 -45.02 209.20 1279.50 -83.65 2185.70 2064.30 5.88
TAX 79.30 155.50 -49.00 50.20 334.00 -84.97 580.60 732.80 -20.77
Deferred Tax 25.80 -4.70 -648.94 -3.30 -15.10 -78.15 -15.90 -62.70 -74.64
PAT 248.40 440.50 -43.61 159.00 945.50 -83.18 1605.10 1331.50 20.55
Equity 246.60 246.60 0.00 246.60 246.60 0.00 246.60 246.60 0.00
PBIDTM(%) 12.70 19.56 -35.06 10.34 20.59 -49.80 17.78 19.06 -6.69

Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×